Immunome Stock Surges on Positive Clinical Trial Results
Immunome shares rose 48% in three months after Phase 3 trial results for desmoid tumor drug Varegacestat showed 84% reduced progression risk. FDA approval sought in 2026.
Crinetics Stock Upgraded After Trial Shows Positive Results
Goldman Sachs upgraded Crinetics Pharmaceuticals to Buy after trial data showed a 67% reduction in A4 for CAH. Citizens also reported positive early experience with Palsonify, supporting Q4 revenue.
Kymera Therapeutics Stock Downgraded Amid Mixed Analyst Views
Wolfe Research downgraded Kymera Therapeutics to Peer Perform on January 6, removing its $92 price target, while BTIG and Citigroup maintained Buy ratings. The stock had gained over 28% in three months, with Wall Street anticipating further growth.
Dave Ramsey Challenges Financial Pessimism with Data-Driven Speech
Personal finance expert Dave Ramsey criticized widespread financial advice as misleading, citing historical inflation and income data to argue economic conditions are manageable.
FDA Grants Priority Review to Vera Therapeutics' Atacicept for IgAN Treatment
Vera Therapeutics announced FDA priority review for Atacicept's BLA to treat IgAN, with a target action date of July 7, 2026. CEO Marshall Fordyce highlighted its potential as a first-in-class B-cell modulator.
Edgewise Therapeutics Stock Gains After Corporate Update
Edgewise Therapeutics shares rose 3% on January 13 after outlining 2026 priorities, including key drug trial milestones. Analysts maintain positive ratings.
Structure Therapeutics Stock Surges on Positive Obesity Pill Data
Structure Therapeutics shares have risen over 130% in three months after reporting positive clinical trial results for its oral obesity pill, with analysts maintaining bullish ratings.
Alphatec Holdings Reports Strong Preliminary 2025 Results and 2026 Outlook
Alphatec Holdings announced preliminary 2025 financial results on January 12, showing 25% revenue growth and providing a 2026 outlook. The company also entered a strategic agreement with Theradaptive for exclusive U.S. distribution rights to OsteoAdapt.
AMD Stock Rises on TSMC Earnings and Wells Fargo Upgrade
AMD stock surged 6% after TSMC reported strong Q4 2025 earnings. Wells Fargo analyst Aaron Rakers upgraded AMD to 'top pick,' forecasting 55% growth driven by CPU leadership and AI positioning.
Terns Pharmaceuticals Receives Analyst Backing After Positive Drug Data
Terns Pharmaceuticals saw analyst support with Truist and Mizuho reiterating buy ratings after Phase 1 data for its CML drug TERN-701 showed a 64% response rate, with shares up over 300% in three months.
Uber Receives Mixed Analyst Ratings Amid Robotaxi Service Milestone
Uber Technologies received analyst rating updates with varied price targets, while announcing robotaxi service progress including production vehicles and autonomous testing.
AMD Launches New AI Embedded Processors and Expands HPE Partnership
AMD introduced Ryzen AI Embedded processors on Jan 5 for edge AI applications and expanded its collaboration with HPE on Jan 2 for scalable AI infrastructure.
Eli Lilly Reports Positive Trial Results and Announces Ventyx Acquisition
Eli Lilly's Taltz and Zepbound show superior efficacy in a Phase 3b trial for psoriatic arthritis and obesity. The company also agreed to acquire Ventyx Biosciences for about $1.2 billion.
ServiceNow Receives Revised Price Targets Ahead of Earnings
Stifel and Wells Fargo adjusted ServiceNow's price targets in early January, maintaining positive ratings. The updates followed the company's announcement of its Q4 and full-year earnings release date.
Arista Networks Receives Analyst Upgrades and Target Adjustments
Piper Sandler upgraded Arista Networks to Overweight with a $159 price target on January 5, citing 2026 as a 'Year of Refresh.' Melius Research maintained a Buy rating with a $200 target, while Morgan Stanley cut its target to $159 on December 17 but kept an Overweight rating.